Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Date
2024Author
Maen, AbdelrahimGök Yavuz, Betül
Mohamed, Yehia I.
Esmail, Abdullah
Lu, Jianming
Mohamed, Amr
Azmi, Asfar S.
Kaseb, Mohamed
Kasseb, Osama
Li, Dan
Gocio, Michelle
Koçak, Mehmet
Selim, Abdelhafez
Ma, Qing
Kaseb, Ahmed O.
Metadata
Show full item recordCitation
Maen, A., Gök Yavuz, B., Mohamed, Y. I., Esmail, A., Lu, J., Mohamed, A. ... Kaseb, A. O. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology, 15. https://dx.doi.org/10.3389/fphar.2024.1291212Abstract
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.